Indication Overview & Treatment Challenge

Antibiotic Resistance

The discovery of antibiotics in the 1930s fundamentally transformed the way physicians care for patients. Focus shifted from diagnosis, often without means to intervene, to a treatment-centric approach that saves lives.

Now, nearly 70 years later, we’ve reached a critical point in treating infectious diseases: new drugs are not being developed at anywhere near the pace necessary to keep ahead of bacteria’s natural ability to evolve and defend themselves against antibiotics. As a result, some of our most powerful antibiotics are becoming useless. If we do not act now, we risk a future that resembles the days before these “miracle” drugs were developed; one in which people die of common infections, and where many medical interventions and therapies we now take for granted are no longer effective. These include many cancer treatments, elective surgery for joint replacements, many arthritis and psoriasis treatment to name a few.  

Treatment Challenge: Transforming the Threat into a Manageable Problem

Microbial resistance to antibiotics is widespread and growing rapidly. Antibiotic resistant microbes (superbugs) have rendered many antibiotics obsolete. The incidence of hospital- and community-acquired drug resistant infections is skyrocketing; the overarching problem is global and continues to evolve and expand.


The challenge before us is to transform this increasingly urgent threat into a manageable problem. Relying exclusively on the discovery and development of new antibiotics will not provide a lasting solution. Managing the threat of resistant antibiotics and all the problems associated will require a different approach. Enhancing and restoring the efficacy of these antibiotics will play a critical role and will allow us to continue to use the tried and true treatments.

Facts about Antibiotic Resistance:

• Antimicrobial resistance is recognized as one of the greatest threats to human health worldwide.

• Drug-resistant infections take a staggering toll in the United States and across the globe. Just one organism, methicillin resistant Staphylococcus aureus (MRSA), kills more Americans every year than emphysema, HIV/AIDS, Parkinson’s disease, and homicide combined.

• Nearly 2 million Americans per year develop hospital-acquired infections (HAIs), resulting in 99,000 deaths – the vast majority of which are due to antibacterial-resistant pathogens.

• Based on studies of the costs of infections caused by antibiotic-resistant pathogens versus antibiotic- susceptible pathogens, the cost to the U.S. health care system of antibiotic resistant infections is $21 billion to $34 billion each year and more than 8 million additional hospital days.

Please reload